Stocktoria
Protagonist Therapeutics, Inc PTGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-08-11
Protagonist Therapeutics, Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% |
| Net margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% |
| FCF margin | 121.9% | 42.1% | -118.1% | -409.8% | -398.3% |
| Return on assets | -19.5% | 37.0% | -22.1% | -51.4% | -36.1% |
| Return on equity | -21.2% | 40.8% | -23.5% | -59.1% | -41.8% |
| Current ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 |
| Revenue growth | -89.4% | 624.1% | 125.7% | -2.8% | -4.4% |
Source: SEC EDGAR filings · CIK 0001377121 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.